18889881171
Kalkine 0
countryflagUS
Logi

AAPL 201.965 -0.274% MSFT 388.89 0.2785% NVDA 111.9116 1.0854% GOOGL 157.585 -0.9336% GOOG 160.09 -0.8546% AMZN 181.04 -0.593% META 530.8366 -0.1211% AVGO 180.525 1.2138% LLY 761.25 0.9147% TSLA 256.95 1.8229% TSM 157.19 0.8663% V 337.982 0.836% JPM 236.81 0.8904% UNH 583.705 -0.5715% NVO 64.595 -2.2177% WMT 95.78 1.1084% LVMUY 110.62 -2.7431% XOM 104.25 0.8318% LVMHF 553.04 -2.9754% MA 519.7637 1.4252%
AAPL 201.965 -0.274% MSFT 388.89 0.2785% NVDA 111.9116 1.0854% GOOGL 157.585 -0.9336% GOOG 160.09 -0.8546% AMZN 181.04 -0.593% META 530.8366 -0.1211% AVGO 180.525 1.2138% LLY 761.25 0.9147% TSLA 256.95 1.8229% TSM 157.19 0.8663% V 337.982 0.836% JPM 236.81 0.8904% UNH 583.705 -0.5715% NVO 64.595 -2.2177% WMT 95.78 1.1084% LVMUY 110.62 -2.7431% XOM 104.25 0.8318% LVMHF 553.04 -2.9754% MA 519.7637 1.4252%

Rxsight Inc

Healthcare US RXST

14.52USD
0.10(0.69%)

Last update at 2025-04-15T16:45:00Z

Day Range

13.7914.69
LowHigh

52 Week Range

20.6666.54
LowHigh

Fundamentals

  • Previous Close 14.42
  • Market Cap2443.70M
  • Volume584331
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-43.42000M
  • Revenue TTM101.10M
  • Revenue Per Share TTM2.83
  • Gross Profit TTM 21.33M
  • Diluted EPS TTM-1.24

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2019-12-312020-12-312021-12-312022-12-31-60M-40M-20M0M20M40M60M80M100M120M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M50M100M150M200M250M300M350M400M
Total Assets
Total Liabilities

Change in Cash

2019-12-312020-12-312021-12-312022-12-31-45M-40M-35M-30M-25M-20M-15M-10M-5M0M5M10M

Total Operating Cash

2019-12-312020-12-312021-12-312022-12-31-60M-58M-56M-54M-52M-50M-48M-46M-44M-42M-40M-38M-36M-34M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -66.74700M -48.68000M 27.63M 126.24M
Minority interest - - - -
Net income -66.75600M -48.68800M 27.57M 126.22M
Selling general administrative 58.66M 32.80M 15.18M 15.20M
Selling and marketing expenses - - - -
Gross profit 21.33M 4.52M 1.71M -1.81900M
Reconciled depreciation 4.02M 3.99M 4.01M 3.93M
Ebit -63.31800M -52.78700M -35.40500M -46.07000M
Ebitda -61.80100M -52.73300M -30.85000M -40.35400M
Depreciation and amortization 1.52M 0.05M 4.55M 5.72M
Non operating income net other 1.52M 2.77M - -
Operating income -63.31800M -52.78700M -35.40500M -46.07000M
Other operating expenses 112.32M 75.38M 50.08M 48.83M
Interest expense 4.95M 3.68M 0.51M 0.03M
Tax provision 0.00900M 0.00800M 0.06M 0.02M
Interest income 1.52M 0.05M 0.54M 2.31M
Net interest income -3.42900M -3.62800M 0.03M 2.28M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.00900M 0.00800M 0.06M 0.02M
Total revenue 49.01M 22.59M 14.68M 2.24M
Total operating expenses 84.65M 57.30M 37.11M 44.77M
Cost of revenue 27.68M 18.08M 12.97M 4.06M
Total other income expense net -3.42900M 4.11M 63.04M 172.31M
Discontinued operations - - - -
Net income from continuing ops -66.75600M -48.68800M 27.57M 126.22M
Net income applicable to common shares -66.75600M -48.68800M 3.37M 26.13M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 182.55M 150.16M 192.72M 100.68M 110.43M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.52M 2.96M 4.07M 1.37M 1.52M
Total liab 22.19M 60.26M 54.48M 398.21M 415.04M
Total stockholder equity 160.36M 89.90M 138.24M -297.52900M -304.61100M
Deferred long term liab - - - - -
Other current liab 13.19M 11.32M 7.24M 8.75M 4.89M
Common stock 0.04M 0.03M 0.03M 80.78M 56.42M
Capital stock 0.04M 0.03M 0.03M 80.78M 56.42M
Retained earnings -594.64000M -546.03200M -479.27600M -430.58800M -419.85500M
Other liab - - - 136.89M 189.68M
Good will - - - - -
Other assets - 1.53M 0.93M 0.57M 0.98M
Cash 9.69M 11.83M 24.36M 13.99M 7.96M
Cash and equivalents - - - - -
Total current liabilities 20.90M 17.24M 11.08M 11.60M 8.46M
Current deferred revenue 2.04M 1.35M 0.62M 0.44M 0.38M
Net debt -6.68000M 33.16M 20.57M 16.76M -2.44200M
Short term debt 1.80M 1.97M 1.53M 1.27M 0.99M
Short long term debt - - - - -
Short long term debt total 3.01M 44.99M 44.93M 30.75M 5.52M
Other stockholder equity 754.97M 636.00M 424.79M 52.28M 58.78M
Property plant equipment - 10.14M 11.22M 18.61M 19.25M
Total current assets 168.41M 134.56M 176.29M 81.50M 90.20M
Long term investments - - - - -
Net tangible assets - 89.90M 138.24M -430.59100M -419.80900M
Short term investments 117.49M 93.97M 134.97M 54.98M 72.71M
Net receivables 20.28M 10.96M 4.86M 2.87M 0.79M
Long term debt - 40.17M 43.40M 24.40M -
Inventory 17.42M 14.84M 8.03M 8.29M 7.22M
Accounts payable 3.86M 2.60M 1.69M 1.13M 2.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.00500M -0.09500M -0.02000M -0.00300M 0.05M
Additional paid in capital - - - - -
Common stock total equity - 0.03M 0.03M 80.78M 56.42M
Preferred stock total equity - - - - -
Retained earnings total equity - -546.03200M -479.27600M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.15M 1.53M 0.93M 0.57M 0.98M
Deferred long term asset charges - - - - -
Non current assets total 14.14M 15.61M 16.43M 19.18M 20.23M
Capital lease obligations 3.01M 4.83M 5.17M 6.35M 5.52M
Long term debt total - - 43.40M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 42.34M -79.96700M 18.13M -2.38700M
Change to liabilities 5.45M 4.24M -0.95400M 1.13M
Total cashflows from investing activities 39.95M -81.90700M 15.59M -5.87000M
Net borrowings -0.14500M 14.87M 24.86M -0.18500M
Total cash from financing activities 6.33M 137.34M 25.24M 1.33M
Change to operating activities 5.60M 0.87M -3.51100M 1.16M
Net income -66.75600M -48.68800M 27.57M 126.22M
Change in cash -12.57700M 10.72M 5.62M -45.15400M
Begin period cash flow 25.17M 14.46M 8.83M 53.98M
End period cash flow 12.60M 25.17M 14.46M 8.83M
Total cash from operating activities -58.85000M -44.70800M -35.20300M -40.61900M
Issuance of capital stock 6.05M 119.58M - -
Depreciation 4.02M 3.99M 4.01M 3.93M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory -7.55500M -2.11100M -1.30700M -5.47100M
Change to account receivables -6.09400M -1.99600M -2.07600M -0.78900M
Sale purchase of stock -0.58700M 121.93M - -
Other cashflows from financing activities 0.40M 17.79M 25.38M 1.51M
Change to netincome 12.15M 7.22M -59.02700M -166.79800M
Capital expenditures 2.39M 1.94M 2.54M 4.09M
Change receivables -6.09400M -1.99600M - -
Cash flows other operating 0.93M -7.81400M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -12.56800M 10.73M - -
Change in working capital -7.41200M -2.67800M -7.84800M -3.97100M
Stock based compensation 11.40M 7.58M 4.18M 4.60M
Other non cash items -0.10100M 0.49M 0.09M -171.39600M
Free cash flow -61.24300M -46.64800M -37.74200M -44.70500M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RXST
Rxsight Inc		 0.10 0.69% 14.52 - 172.41 22.15 13.34 9.08 -7.7044
ABT
Abbott Laboratories		 -0.58 0.46% 126.79 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -6.34 1.79% 347.08 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.48 0.57% 83.74 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.04 0.04% 94.31 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Rxsight Inc

100 Columbia, Aliso Viejo, CA, United States, 92656

Key Executives

Name Title Year Born
Dr. Ronald M. Kurtz M.D. Pres, CEO & Director 1963
Ms. Shelley B. Thunen CFO & Assistant Sec. 1954
Dr. Ilya Goldshleger Ph.D. Chief Operating Officer 1975
Mr. Eric J. Weinberg Chief Commercial Officer 1961
Rebecca Williston VP of Accounting & Fin. NA
Mr. Matt Haller Ph.D. Chief Technology Officer NA
Steve Everly VP of US Sales NA
Mr. Roy Freeman VP of Marketing NA
Caroline Vaughn VP of HR NA
Scott Gaines Sr. VP of Commercial Operations & Bus. Process NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.